Literature DB >> 15659114

Construction of phospholamban antisense RNA recombinant adeno-associated virus vector and its effects in rat cardiomyocytes.

Jiang Li1, Shen-jiang Hu, Jian Sun, Zhao-hui Zhu, Xia Zheng, Guo-zhong Wang, Yu-mei Yao, Nai-yun Chen, Xiao-yan Zhao.   

Abstract

AIM: To construct a recombinant adeno-associated virus (rAAV) vector containing gene encoding phospholamban antisense RNA (asPLB), and analyse its effect on expression of PLB, expression and activity of sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), and the change of intracellular free Ca2+ concentration ([Ca2+]i) in rat cardiomyocytes.
METHODS: The target gene encoding PLB antisense RNA was inserted inversely into the adeno-associated virus plasmid pAAV-MCS digested by corresponding restricted endonuclease enzyme. The recombinant plasmid and pAAV-RC and pHelper were co-transfected into 293 cell. At the same time, a viral production positive control (rAAV-LacZ) and negative control were performed. The recombinant viruses were used to transfect the cultured rat cardiomyocytes. Site beta-Galactosidase staining were performed to observe the transfer efficiency. Reverse transcription-PCR and Western blot were used to determine the mRNA and protein expression of PLB and SERCA. The activity of SERCA and the [Ca2+]i were measured.
RESULTS: The rAAV vectors were constructed successfully and were transfected into rat cardiomyocytes effectively. The PLB mRNA and protein expression were reduced in rat cardiomyocytes transfected by rAAV-asPLB compared with controls. The activity of SERCA was increased. In rest state, the level of [Ca2+]i in the rAAV-asPLB transfected group decreased. The level of [Ca2+]i increased when induced by isoproterenol.
CONCLUSION: AAV-asPLB vector was constructed successfully, which disrupted the expression of PLB, enhanced the activity of SERCA, reduced the resting [Ca2+]i, and improved the cardiac function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659114     DOI: 10.1111/j.1745-7254.2005.00006.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

Review 1.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

2.  rAAV-mediated angiogenin gene transfer induces angiogenesis and modifies left ventricular remodeling in rats with myocardial infarction.

Authors:  Xiao-Yan Zhao; Shen-Jiang Hu; Jiang Li; Yun Mou; Chi-Fung Chan; Juan Jin; Jian Sun; Zhao-Hui Zhu
Journal:  J Mol Med (Berl)       Date:  2006-09-06       Impact factor: 4.599

3.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 4.  SERCA2a in heart failure: role and therapeutic prospects.

Authors:  Davide Gianni; Joachim Chan; Judith K Gwathmey; Federica del Monte; Roger J Hajjar
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.